Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$38.0B
447M shares
52-week range
$56.37 – $110.09
54% from low
Exchange
NYSE
CS
P/S (TTM)
5.5
EV / FCF (TTM)
38.7
Viking Holdings Ltd is a travel company, with a fleet of 92 small ships, which view as floating hotels. It offers travel experiences on all seven continents in all three categories of the cruise industry river, ocean, and expedition cruising. The Group defines its products based on the type of cruise offering and language of the cruise service. The River segment provides river cruises outside the United States to English-speaking passengers. The Ocean segment offers ocean cruises to English-speaking passengers. Other include operating segments that are not individually reportable, consisting of expedition cruises for English-speaking passengers (Expedition), Mississippi River cruises for English-speaking passengers, and Viking China, which includes cruises for Mandarin.
www.viking.comNo one on the platform currently holds VIK.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 759,204 | $55.8M |
No one on the platform has traded VIK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 48.7% | — | — | — | ||
| Rev. Growth % | 21.9% | |||||
| Profit Margin % | 17.7% | -68.8% | ||||
| Free Cash Flow Margin % | 20.0% | -0.6% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +12.6% on the P/E track.
At today's price, your expected annual return is +18.5% on the P/E track.
At today's price, your expected annual return is +23.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.4B | +15.4% | $3.26 | $3.16–$3.33 | 26.2× | 10 |
| 2027 | $9.0B | +21.3% | $4.39 | $4.14–$4.56 | 19.4× | 10 |
| 2028 | $10.2B | +13.6% | $5.39 | $5.25–$5.57 | 15.8× | 5 |
| 2029 | $11.4B | +12.5% | $6.50 | $6.33–$6.71 | 13.1× | 4 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-19 | $1.26 | $1.31 | +4.0% |
| 2026-05-14 | $-0.11 | $-0.11 | +1.9% |
| 2026-03-03 | $0.54 | $0.67 | +23.2% |
| 2025-11-19 | $1.20 | $1.20 | +0.0% |
| 2025-08-19 | $0.99 | $0.99 | -0.5% |
| 2025-05-20 | $-0.29 | $-0.24 | +18.4% |
| 2025-03-11 | $0.36 | $0.45 | +23.4% |
| 2024-11-19 | $0.85 |
| $0.89 |
| +4.7% |
| $19.9B |
| — |
| PHMPulteGroup, Inc. | $118.94 | +0.57% | $23.0B | — |
| ROLRollins, Inc. | $35.31 | +1.67% | $17.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Viking Holdings’ board authorized a share repurchase program of up to $1 billion, with management saying the move reflects confidence in the company’s long-term outlook and ability to generate substantial cash flow. CEO Leah Talactac said the authorization provides flexibility to return capital to shareholders while continuing to invest in the fleet, customer experience and future growth opportunities. The announcement came after Citi placed the stock under a 30-day downside catalyst watch during regular trading, briefly pressuring shares. The buyback more than reversed that sentiment after hours, as investors appeared to view the capital-return plan as a stronger signal of management’s confidence in the stock’s intrinsic value. The broader market was largely flat, while cruise operators continue to face concerns over low European river-water levels affecting third-quarter operations. $VIK
View on StockTwits ↗
In the past month, $NCLH lost 24%, $RCL lost 18%, and $VIK lost 20%, $CCL lost 21%. Oil is up $20 but do you really think the entire cruise industry deserves a loss of 20-25% value? It’s pure short manipulation. If fundamentals matter, RCL would have stayed flat.
View on StockTwits ↗
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research
View on StockTwits ↗
RECAP 9/8 +Pos Comments: $HCM + HSBC $BCRX + TD Cowen $VIK + UBS RECAP 9/8 -Neg Comments: $CRM - Accountability Research Live Breaking trading news www.openoutcrier.com
View on StockTwits ↗
$NCLH $CCL $VIK $RCL here we go…I just saw the talking heads on CNBC have an “expert” on talking about valuations being too lofty. Sure, run this story when the Dow is down 600 points. Ah the gloom and boomers need clicks I guess. Ugh!
View on StockTwits ↗
$VIK *VIKING GAINS 2% AFTER UBS REPORT THAT NOTES BETTER RIVER LEVELS
View on StockTwits ↗
$LEXX The CEO dropped a HUGE hidden nugget in the latest PR that the market completely glossed over in my opinion. He explicitly confirmed LEXX will announce their 2027 R&D plans in the coming months. Why does this matter? 👇 1️⃣ Commercial Deal Negotiations: Companies don't map out multi-year trial pipelines in a vacuum—they align them with active out-licensing & co-development partner talks! 🤝 They are actively working to secure a commercial deal imo. 2️⃣ Perpetual "Cash Loop": Recycling the $2.6M USD rebate back into Australian trials means ~43.5% non-dilutive refunds ON REPEAT to fund 2027 R&D! 💰 3️⃣ Maximum Partner Leverage: Proves to PharmaCO & PegBio that Lexaria isn’t waiting around. The platform moves forward with or without them! 💪 With Human Study #7 GLP-1 readout imminent the setup is absolute fire! 🔥 $LLY $NVO $RANI $VIK #Biotech #GLP1 https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-receives-usd2.6-million-tax-rebate-payment-1214902
View on StockTwits ↗
$LEXX is coiling for a MASSIVE breakout! 🚀🔥 Key catalysts aligned: ✅ $2.6M USD cash tax rebate secured = NO short-term dilution! 💰 ✅ Debt-free balance sheet with runway deep into 2027 🛡️ ✅ Resistance cleared! $12.00–$12.30 converted to solid support 🎯 ✅ Next technical price target: $13.50 – $15.00+ 📈 ✅ Tight 1.65M share float = low liquidity on the ask, ripe for a squeeze 🩳💥 🔥 BIGGEST CATALYST AHEAD: Human Study #7 GLP-1 top-line PK results dropping soon! Head-to-head steady-state data vs. Wegovy® tablets could drive a major revaluation before commercial deals even hit. Don't sleep on this coiling spring! 💎🙌 LFG! $LLY $NVO $RANI $VIK #Biotech #GLP1 #DehydraTECH
View on StockTwits ↗$LEXX Algos will jump on this breakout hard tomorrow if we get a nice close. $RANI $VIK $LLY $NVO #GLP1
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.